Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Mark D. Tyson, II, MD, MPH
Advertisement
Articles by Mark D. Tyson, II, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
2
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
3
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
